Anti-salusin-β antibody enhances angiogenesis after myocardial ischemia reperfusion injury
| العنوان: | Anti-salusin-β antibody enhances angiogenesis after myocardial ischemia reperfusion injury |
|---|---|
| المؤلفون: | Masahito Ogawa, Jun-ichi Suzuki, Masayoshi Shichiri, Ryo Watanabe, Issei Komuro, Mayumi Masumura, Ayako Nagashima, Mitsuaki Isobe |
| المصدر: | Expert Opinion on Therapeutic Targets. 17:1003-1009 |
| بيانات النشر: | Informa Healthcare, 2013. |
| سنة النشر: | 2013 |
| مصطلحات موضوعية: | Male, Vascular Endothelial Growth Factor A, medicine.medical_specialty, Vascular smooth muscle, Angiogenesis, Clinical Biochemistry, Neovascularization, Physiologic, Myocardial Reperfusion Injury, Endogeny, Pharmacology, Anterior Descending Coronary Artery, Antibodies, Cell Line, Muscle hypertrophy, Rats, Sprague-Dawley, Neovascularization, Internal medicine, Drug Discovery, medicine, Animals, Humans, Cells, Cultured, Chemokine CCL2, business.industry, Macrophages, Myocardium, Interleukin-8, Fibroblasts, medicine.disease, Rats, Matrix Metalloproteinase 9, Cardiology, Intercellular Signaling Peptides and Proteins, Matrix Metalloproteinase 2, Molecular Medicine, Immunohistochemistry, medicine.symptom, business, Reperfusion injury |
| الوصف: | Salusins are multifunctional endogenous bioactive peptides simultaneously biosynthesized from their precursor prosalusin. Salusin-β stimulates proliferation of vascular smooth muscle cells and fibroblasts and regulates myocardial growth and hypertrophy. Salusin-β has potent hypotensive, bradycardic and proatherosclerotic effects.To investigate whether salusin-β plays a role in myocardial remodeling after myocardial ischemia reperfusion (I/R) injury, rat I/R models were created by the left anterior descending coronary artery occlusion for 30 min, followed by 24 h or 7 days of reperfusion (control, n = 6 each).Immunohistochemical double staining showed the enhanced expression of salusin-β in the macrophages around myocardial ischemic area. Anti-salusin-β treated groups were administered the neutralizing salusin-β antibody (10 μl/day, i.p.) once daily from day -1 to day 1 or from day -1 to day 7 (anti-salusin-β, n = 6 each). The anti-salusin-β therapy enhanced myocardial angiogenesis in the peri-ischemic area of reperfusion. The small vessels (40 μm in diameter) of I/R hearts treated with anti-salusin-β were more densely populated than those of control animals (108.5 ± 19.7 vs 47.5 ± 2.4, p0.05). Real-time PCR revealed that the anti-salusin-β therapy-induced angiogenesis was not associated with enhanced vascular endothelial growth factor A expression. The authors, for the first time, have clarified that endogenous salusin-β suppresses angiogenesis which is critical in the development of cardiac remodeling following I/R injury. |
| تدمد: | 1744-7631 1472-8222 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13c91cb14d13632a6071a930afac6045 https://doi.org/10.1517/14728222.2013.819852 |
| رقم الأكسشن: | edsair.doi.dedup.....13c91cb14d13632a6071a930afac6045 |
| قاعدة البيانات: | OpenAIRE |
PDF full text from Publisher | تدمد: | 17447631 14728222 |
|---|